Journal article
Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy
PV Sepulveda, S Lamon, A Hagg, RE Thomson, CE Winbanks, H Qian, CR Bruce, AP Russell, P Gregorevic
Scientific Reports | NATURE PORTFOLIO | Published : 2015
DOI: 10.1038/srep17535
Open access
Abstract
Follistatin is an inhibitor of TGF-β superfamily ligands that repress skeletal muscle growth and promote muscle wasting. Accordingly, follistatin has emerged as a potential therapeutic to ameliorate the deleterious effects of muscle atrophy. However, it remains unclear whether the anabolic effects of follistatin are conserved across different modes of non-degenerative muscle wasting. In this study, the delivery of a recombinant adeno-associated viral vector expressing follistatin (rAAV:Fst) to the hind-limb musculature of mice two weeks prior to denervation or tenotomy promoted muscle hypertrophy that was sufficient to preserve muscle mass comparable to that of untreated sham-operated muscle..
View full abstractGrants
Awarded by State Government of Victoria
Funding Acknowledgements
This work was supported by Project Grant funding from the National Health and Medical Research Council (NH&MRC) of Australia (526648 awarded to PG). PG is supported by a NH&MRC Career Development Fellowship (1046782) and previously, a Senior Research Fellowship sponsored by Pfizer Australia. The Baker IDI Heart & Diabetes Institute is supported in part by the Operational Infrastructure Support Program of the Victorian Government.